| Literature DB >> 29383029 |
Abstract
Colorectal cancer is the third most common cancer worldwide and the second most common cause of cancer-related death in Europe and North America. Colonoscopy is the gold standard investigation for the colon but is not perfect, and small or flat adenomas can be missed which increases the risk of patients subsequently developing colorectal cancer. Adenoma detection rate is the most widely used marker of quality, and low rates are associated with increased rates of post-colonoscopy colorectal cancer. Standards of colonoscopy and adenoma detection vary widely between different endoscopists. Interventions to improve adenoma detection rate are therefore required. Many devices have been purported to increase adenoma detection rate. This review looks at current available evidence for device technology to improve adenoma detection rate during colonoscopy.Entities:
Keywords: adenoma detection rate; colonoscopy; colorectal cancer; colorectal polyps; post-colonoscopy colorectal cancer
Year: 2018 PMID: 29383029 PMCID: PMC5784538 DOI: 10.1177/1756283X17746311
Source DB: PubMed Journal: Therap Adv Gastroenterol ISSN: 1756-283X Impact factor: 4.409
Levels of evidence for devices in colonoscopy.
| Study | Level of evidence | Measures used | Primary outcome | Patients ( | Main outcomes |
|---|---|---|---|---|---|
|
| |||||
| Pellisé and colleagues[ | 2 | SD | ADR | 620 | No significant difference in ADR in both groups |
| Tribonias and colleagues[ | 2 | SD | PDR | 390 | Overall polyp rate higher in HDWE group (SD 1.31 ± 1.90; HDWE 1.76 ± 2.31, |
| Longcroft-Wheaton and colleagues[ | 2 | SD | ADR (<10 mm in size) | 170 | No significant difference in ADR in both groups |
| Buchner and colleagues[ | 3 | SD | ADR | 2430 | ADR 4.5% higher in HD group ( |
| East and colleagues[ | 3 | SD | ADR | 130 | No significant difference in ADR in both groups |
| Burke and colleagues[ | 3 | SD | ADR | 852 | No significant difference in ADR in both groups |
| Erim[ | 3 | SD | PDR | 900 | No significant difference in ADR in both groups |
| Jrebi and colleagues[ | 3 | SD | ADR, PDR | 1268 | ADR higher in HD group (30.4% |
| Bond and colleagues[ | 3 | SD | ADR, MAP | 395 | ADR 12.6% higher with HD ( |
|
| |||||
| Brown and colleagues[ | 1 | CE | PDR, diminutive lesions, number of participants with multiple neoplastic lesions | 2727 | CE group found more people with at least one neoplastic lesion [odds ratio (OR) 1.53, 95% confidence interval (CI) 1.31–1.79; 7 trials; 2727 participants], and at least one diminutive neoplastic lesion (OR 1.51, 95% CI 1.19–1.92; 4 trials; 1757 participants) |
|
| |||||
| Nagorni and colleagues[ | 1 | NBI | PDR | 3673 | No significant difference in both groups |
| Senore and colleagues[ | 2 | NBI | ADR | 117 | No significant difference in both groups |
| East and colleagues[ | 2 | NBI | ADR | 214 | No significant difference in both groups |
| Ikematsu and colleagues[ | 2 | NBI-SD | ADR/AMR | 813 | No significant difference for ADR in both groups |
| Adler and colleagues[ | 2 | NBI | ADR | 401 | No significant difference in both groups |
| Gilani and colleagues[ | 2 | SD-NBI | ADR | 300 | No significant difference in both groups |
| Gross and colleagues[ | 2 | SD-HDNBI | PMR | 96 | Polyp miss rates lower with HDNBI-SD (31% |
| Rastogi and colleagues[ | 2 | SDWL | ADR | 630 | No significant difference in ADR in both groups |
|
| |||||
| Chung and colleagues[ | 2 | NBI | ADR | 1650 | No significant difference in all three groups for ADR |
| Chung and colleagues[ | 2 | FICE-SDWL | AMR | 359 | No significant difference in both groups |
| Yoshida and colleagues[ | 2 | NBI-FICE | AMR | 55 | No significant difference in both groups |
| Kang and colleagues[ | 2 | NBI | ADR | 955 | No significant difference in both groups |
|
| |||||
| Zhao and colleagues[ | 1 | WL-AFI | ADR, PDR, AMR, PMR | 1199 | No significant difference in both groups for ADR and PDR |
| Moriichi and colleagues[ | 3 | Back-to-back SD and AFI | ADR | 88 | ADR increase by 8% |
| Hoffman and colleagues[ | 2 | SD | ADR | 220 | ADR 38% i-SCAN |
| Hong and colleagues[ | 2 | HDWL-HDWL, i-SCAN1-HDWL, i-SCAN2-HDWL | ADR | 389 | No improvement in ADR but i-SCAN effective for real-time histologic prediction of polyps |
| Chan and colleagues[ | 3 | HDWL | Predicting polyp histology | 75 | No significant difference in both groups |
| Pigò and colleagues[ | 3 | HDWL | Predicting polyp histology | 78 | i-SCAN helps assist in real-time prediction of histology with 95% sensitivity, 82% specificity and 92% accuracy |
| Basford and colleagues[ | 3 | HDWL | Predicting polyp histology | 84 | No significant difference in both groups |
| Bowman and colleagues[ | 3 | HDWL | ADR | 1936 | ADR higher with i-SCAN (618 |
| Kim and colleagues[ | 3 | HDWL | PDR | 501 | PDR higher with i-SCAN (52% |
| Rodríguez-D’Jesus and Saperas[ | 3 | HDWL | Diagnostic yield | 155 | No significant difference |
|
| |||||
| Kuiper and colleagues[ | 2 | ETMI (HRE-AFI) | ADR | 234 | No significant difference in both groups |
| Van den Broek and colleagues[ | 2 | HRE-AFI | AMR | 100 | No significant difference in both groups |
| Rotondano and colleagues[ | 2 | HRE-AFI | AMR | 94 | No significant difference in both groups |
|
| |||||
| Morgan and colleagues[ | 1 | CAC | Efficacy of colonoscopy as diagnostic tool | 5932 | May improve caecal intubation time, PDR and pain |
| Pohl and colleagues[ | 1 | CAC | ADR | 1113 | No significant difference in ADR |
| Desai and colleagues[ | 1 | CAC | Right-sided ADRs | 686 | Improvement in right-sided ADR with CAC (23% |
| Rastogi and colleagues[ | 2 | CAC | ADR | 420 | Higher ADR with CAC 69% |
| De Wijkerslooth and colleagues[ | 2 | CAC | ADR | 1380 | No change in ADR but improve patient comfort scores |
| Othman and colleagues[ | 2 | CAC | ADR | 440 | No improvement in ADR |
| Hewett and Rex[ | 2 | CAC-SD | AMR | 67 | CAC lower miss rate 21% |
| Horiuchi and colleagues[ | 2 | CAC | ADR | 107 | No significant difference in ADR |
| Harada and colleagues[ | 2 | CAC | PDR, CIT, patient comfort | 592 | No significant change in PDR but lower patient discomfort scores |
| Tee and colleagues[ | 2 | CAC | CIT | 400 | No change in PDR or caecal intubation time |
| Frieling and colleagues[ | 2 | CAC | PDR | 504 | No significant difference in PDR |
| Floer and colleagues[ | 2 | EAC | ADR | 500 | ADR significantly increased 35.4% |
| Biecker and colleagues[ | 2 | EAC | PDR | 498 | PDR increased with EAC (56% |
| Van Doorn and colleagues[ | 2 | EAC | ADR | 1063 | No significant difference in ADR in both groups |
| De Palma and colleagues[ | 2 | EAC | ADR | 288 | ADR improved with EAC (29.6% |
| Bhattacharyya and colleagues[ | 2 | EAC | ADR | 534 | No significant difference in ADR |
| Ngu and colleagues[ | 2 | EAC | ADR | 1772 | ADR improved by 4.8% ( |
| Sawatzki and colleagues[ | 3 | EAC | ADR | 104 | ADR of 47% screening population by experienced endoscopists |
| Dik and colleagues[ | 2 | EndoRings-SD | AMR | 116 | Adenoma miss rate in EndoRings group lower (10.4% |
|
| |||||
| Gralnek and colleagues[ | 2 | SD-FUSE | AMR | 185 | Adenoma miss rate lower in FUSE group 7% |
| Hassan and colleagues[ | 2 | FUSE | AMR | 658 | No significant improvement in ADR |
| Papanikolaou and colleagues[ | 2 | SD-FUSE | AMR | 215 | Adenoma miss rate lower in FUSE group 10.9% (95% CI 3.8–18.1) |
| Ito and colleagues[ | 3 | FUSE | ADR | 130 | No significant improvement in ADR |
| Gralnek and colleagues[ | 3 | FUSE | Feasibility, usability, safety | 50 | Safe to use |
| Song and colleagues[ | 3 | FUSE | Feasibility | 262 | Safe to use |
|
| |||||
| Leufkens and colleagues[ | 2 | Tandem SC-TEC | ADR | 395 | Net additional ADRs 23.3% for adenomas |
| Halpern and colleagues[ | 2 | SD-NaviAid | AMR | 126 | Adenoma miss rate lower in NaviAid group 7.5% |
| Gralnek and colleagues[ | 3 | NaviAid | Safety and feasibility | 47 | Safe and feasible |
| Vucelic and colleagues[ | 4 | Aer-o-scope | Extent of colonic intubation | 12 | 83% caecal intubation rate |
|
| |||||
| Hafner and colleagues[ | 1 | Water-aided | Technical quality, screening efficacy, patient acceptance | 2933 | Main benefit is reduction in procedure-related abdominal pain which may enhance acceptance of screening/surveillance colonoscopy. Some improvement in ADR likely due to cleansing effects of water |
| Cadoni and colleagues[ | 2 | WE | To assess ADR in the right colon | 1200 | Water exchange colonoscopy achieved significantly higher ADR (<10 mm adenomas) in the right colon |
ADR, adenoma detection rate; AICD, air insufflation colonoscopy; AMR, adenoma miss rate; CE, conventional chromo-endoscopy; EAC, Endocuff-assisted colonoscopy; ETMI, endoscopic trimodal imaging; EVAC, Endocuff Vision-assisted colonoscopy; FICE, Fuji Intelligent Color Enhancement; FUSE, full spectrum endoscopy; HD, high-definition colonoscopy; HDNBI, high-definition narrow-band imaging colonoscopy; HDWE, high-definition wide-angle colonoscopy; HDWL, high-definition white-light colonoscopy; HRE, high-resolution endoscopy; NBI, narrow-band imaging colonoscopy; PDR, polyp detection rate; SD, standard-definition colonoscopy; SDWL, standard-definition white-light colonoscopy; TEC, Third-Eye Retroscope; WE, water exchange colonoscopy; WI, water immersion colonoscopy.